RhumbLine Advisers’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

RhumbLine Advisers’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-53,286	Closed	-$2.48M	–	4414
2023 Q2	$2.48M	Sell	53,286 -979	-2%	-$33.8K	﹤0.01%	1788
2023 Q1	$1.56M	Buy	54,265 +2,675	+5%	+$79.2K	﹤0.01%	1940
2022 Q4	$1.61M	Buy	51,590 +9,099	+21%	+$297K	﹤0.01%	1900
2022 Q3	$862K	Buy	42,491 +2,469	+6%	+$45K	﹤0.01%	2225
2022 Q2	$621K	Buy	40,022 +25,432	+174%	+$437K	﹤0.01%	2377
2022 Q1	$279K	Buy	14,590 +4,258	+41%	+$76K	﹤0.01%	2661
2021 Q4	$262K	Buy	+10,332	New	+$303K	﹤0.01%	2753

RhumbLine Advisers's DICE Position: Q3 2023 in Review

RhumbLine Advisers sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 53,286 shares — an estimated $2.48M sold.

RhumbLine Advisers first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $2.48M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

RhumbLine Advisers reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
RhumbLine Advisers sold 53,286 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.48M.
RhumbLine Advisers first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
RhumbLine Advisers's DICE Therapeutics, Inc. Common Stock position peaked at $2.48M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.